News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences, Inc. (GILD), MicroDose Therapeutx (formerly MicroDose Technologies Inc) Ink License Deal For MDT-637



4/20/2011 8:18:53 AM

Xconomy -- Gilead Sciences (NASDAQ: GILD) said today it has obtained a license from MicroDose Therapeutx to an inhalable small molecule drug for respiratory syncytial virus (RSV). Foster City-based Gilead agreed to make an upfront cash payment, research funding, milestone payments, and royalties on product sales to Monmouth Junction, NJ-based MicroDose. The dollar amount of the deal wasn’t disclosed. RSV infections are estimated to cause 125,000 infants to be hospitalized each year.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES